Test Brochures / Case Studies
Published Posters
ASH 2024

Establishing a Distinct Cytokine Signature for Multiple Myeloma
Using Bone Marrow RNA and Peripheral Blood Cell-Free RNA (cfRNA)

Establishing Distinct Cytokine Signatures Differentiating between Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Chip Using Bone Marrow RNA or Cell-Free RNA (cfRNA)

Establishing Lymphoma Type-Specific Cytokine Signatures
Using Tissue-Based RNA or Peripheral Blood Cell-Free RNA (cfRNA)

Clonotype- naive Detection Of Clonality in Patients Suspected of Having Multiple Myeloma or Monoclonal Gammopathy Using Peripheral Blood Cell-Free RNA (cfRNA)
ASCO 2024

Multiple Alternative Splicing of HER2 transcripts
and Exon Skipping with Potential
Consequences on Function and Antibody-Based Therapy

Using Cell-Free RNA in Monitoring Immune System and the Demonstration of Significant Systemic Deficiency in Lymphoid and Myeloid Biomarkers in Patients with Cancer
ASCO 2023

Distinguishing between cancer-related mutations and clonal hematopoiesis using cell-free RNA (cfRNA) expression levels in a machine learning model

Defining the immune microenvironment
in myelodysplastic syndrome
and acute myeloid leukemia
using machine learning

Using machine learning to characterize lung cancer microenvironment and the development of a model to predict the presence of similar microenvironment in other cancers
ASH 2023

USING NEXT GENERATION SEQUENCING OF FLOW CYTOMETRY CD MARKERS AND MACHINE LEARNING AS A REPLACEMENT TO FLOW CYTOMETRY ANALYSIS FOR THE DIAGNOSIS OF HEMATOLOGIC NEOPLASMS

LYMPHOMA DIAGNOSIS AND CLASSIFICATION USING NEXT
GENERATION SEQUENCING OF 30 CD MARKERS AND MACHINE
LEARNING AS AN ALTERNATIVE TO IMMUNOHISTOCHEMISTRY
AACR 2023

Predicting PD-L1 Status in Solid Tumors Using Transcriptomic Data and Artificial Intelligence Algorithms

The Molecular Landscape of Premenopausal Versus Postmenopausal Breast Cancer in Patients Without Inherited Predisposition Mutations

Real-world transcriptomic biomarkers as replacement for immunohistochemistry and FISH studies in breast cancer
ASCO 2022

Combining cell-free RNA (cfRNA) with cell-free total nucleic acid (cfTNA) as a new paradigm for liquid biopsy

Cell-free RNA in liquid biopsy and biomarkers profiling of hematologic and solid tumors
